DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zllpwr/targeting_immune) has announced the addition of the "Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update 2014" report to their offering.
The Targeting Immune Checkpoints in Cancer Immunotherapy: Drug Pipeline Update is the most up to date and comprehensive pipeline review and competitive assessment you can get on this hot and fast moving area in cancer immunology. There are two sides of immune checkpoint control; those which activate and those which inhibit T-cell activation. the author's Targeting Immune Checkpoints in Cancer Immunotherapy: Drug Pipeline Update covers both sides extensively.
There are currently three approved immune check point inhibitors, namely Yervoy (ipilimumab), Keytruda (Pembrolizumab) and Opdivo (nivolumab). Bristol-Myers Squibb's Yervoy, a CTLA4 targeting antibody, was first to be approved in 2011 for the treatment of patients with unresectable or metastatic melanoma. In 2013 world-wide sales on Yervoy alone was close to $1 billion dollars ($960 million). In 2014 came two more approvals, Opdivo was first approved in Japan through Ono Pharmaceutical and later followed by Merck & Co's Keytruda. Both Keytruda and Opdivo are PD-1 inhibitors and were approved for treatment of melanoma.
Apart from a quite substantial drug pipeline targeting immune checkpoints in cancer the industry is also highly prolific generating combination therapy agreements with each other, leaving very little on the table for late comers.
Drug Pipeline Update at a Glance
Includes more than 59 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.
Note: You are able to sort and find drugs according to companies and partners from drop-down menus in the application. You may also sort and find drugs according to country of companies.
Drug name & Synonyms
Lists commercial, generic and code names for drugs.
This Drug Pipeline Update contains 109 immune checkpoints drugs in development, which have a total of 309 developmental projects in cancer. In addition there are suspended and ceased drugs.
Pipeline Breakdown According to Number of Drugs
- Marketed# 3
- Pre-registration# 1
- Phase III# 9
- Phase II# 20
- Phase I# 33
- Preclinical# 47
- Suspended# 3
- Ceased# 14
For more information visit http://www.researchandmarkets.com/research/zllpwr/targeting_immune